2026-01-19 - Analysis Report
**Financial Report for Novo Nordisk (NVO)**

**Company Overview**
Novo Nordisk - 비만/당뇨 치료제 (Global Leader)

**Return Rate Comparison**
* Cumulative return of NVO: 22.78%
* Cumulative return of VOO (S&P 500): 82.54%
* Current divergence: 59.76% (difference in cumulative return on the last day of the data)

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -2.0% | 14.7% | -2.0% | 0.8 | 102.4B |
| 2017-2019  | 24.0% | 9.5% | 15.0% | 0.6 | 128.6B |
| 2018-2020  | 4.0% | 9.5% | -17.0% | 0.6 | 155.2B |
| 2019-2021  | 34.0% | 12.4% | -3.0% | 0.6 | 248.8B |
| 2020-2022  | 52.0% | 16.4% | 42.0% | 0.6 | 300.7B |
| 2021-2023  | 84.0% | 16.4% | 68.0% | 0.5 | 459.7B |
| 2022-2024  | 13.0% | 37.7% | -13.0% | 0.5 | 382.2B |
| 2023-2025  | -56.0% | 55.6% | -105.0% | 0.7 | 226.1B |

**Recent Stock Price Fluctuations**

* Close: $62.33
* 5-day SMA: $59.57
* 20-day SMA: $54.41
* 60-day SMA: $50.73

**Market Risk Indicator (MRI) and Key Indicators**

* MRI: 0.80 (High investment recommended)
* RSI: 76.91
* PPO: 1.05
* Hybrid Signal: Buy (Cash 1%)
* Risk Level: Medium (MRI 0.80)

**Recent relative divergence change: 0.0 (flat)**

**Sharp Rebound/Decline Alert**
Recent price fluctuation is sharp ($9.12 in one day). This may be a sign of market volatility.

**News & Significant Events**

* Novo's Wegovy Pill Looks A Lot Like Zepbound — In One Week
* Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?
* Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus
* Novo Nordisk wins 3,071 prescriptions for Wegovy pill (NVO:NYSE)
* NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As 'Fair Value'
* Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more

**Analyst Opinions**

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
	+ Opinions: 11
	+ Target Price (avg/high/low): 55.71 / 73.05 / 41.43

**Comprehensive Analysis**
NVO's cumulative return is significantly lower than VOO's, but recent price fluctuations are sharp. Market risk indicator suggests a medium risk level. Analyst consensus is neutral with a buy recommendation. Recent news highlights the effectiveness of Wegovy Pill, which may positively impact NVO's stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.